Skip to content

Epididymis Protein 4 and Pulmonary Function With Quality Improvement Protocol Among Cystic Fibrosis Patients

Serum Human Epididymis Protein 4 and Pulmonary Function Before and After Structural Quality Improvement Protocol Among Cystic Fibrosis Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06915961
Enrollment
35
Registered
2025-04-08
Start date
2024-10-07
Completion date
2025-12-12
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis (CF)

Keywords

Quality Improvement (QI)

Brief summary

To implement a quality improvement plan aimed at achieving a 5% increase in the Forced expiratory volume in 1st second (FEV1) (% predicted value) in cystic fibrosis (CF) patients with impaired pulmonary function parameters over 12 months. Additionally, the plan aims to measure serum human epididymis protein 4 (HE4) levels in the studied subjects before and after pulmonary function improvement.

Detailed description

This study will be conducted on 35 children diagnosed with cystic fibrosis, aged between 6 and 18 years. Patients will be selected during their follow-up visits to the Pediatric Chest Clinic at Ain Shams University Hospital. Inclusion Criteria: A. Pediatric cystic fibrosis patients diagnosed based on the Consensus Guidelines from the Cystic Fibrosis Foundation, with a positive sweat chloride test (≥60 milliequivalent/L) and/or the presence of two cystic fibrosis disease-causing gene mutations. B. Age ≥6 years. C. Forced expiratory volume in 1st second (FEV₁) ≤80%. Exclusion Criteria: A. Patients unable to perform spirometry. All subjects in the study will undergo an interventional quality improvement plan. A specialized clinic for CF patients will be established based on the quality improvement (QI) plan, where patients will be followed up every three months by a specialized multidisciplinary team, including a pediatric pulmonologist, pediatric nutrition consultant, pediatric gastroenterologist, chest physiotherapist, and pediatric endocrinologist. Each specialized clinic will develop and implement standardized cystic fibrosis care algorithms and individualized treatment plans for each patient. These algorithms and plans will be continuously adjusted based on challenges encountered during follow-up to address barriers and deficiencies that may contribute to poor outcomes. Areas needing improvement will be identified, and appropriate resources and strategies will be proposed. This will include the development of fishbone diagrams, flowcharts, Plan-Do-Study-Act (PDSA) cycles, PDSA ramps, and other quality improvement tools to address specific deficiencies. Additionally, training and engaging the team in quality improvement methodologies will be conducted. Patients will undergo pulmonary function tests at baseline, followed by assessments at six months and one year during the study.

Interventions

None listed

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pediatric CF patients diagnosed based on the Consensus Guidelines from the Cystic Fibrosis Foundation, with a positive sweat chloride test (≥60 milliequivalent/L) and/or the presence of two CF disease-causing gene mutations. * Age ≥6 years. * Forced expiratory volume in 1 second (FEV₁) ≤80%.

Exclusion criteria

●Patients are unable to perform spirometry.

Design outcomes

Primary

MeasureTime frameDescription
Quality Improvement Protocol for Achieving a 5% Increase in FEV₁% Predicted Value in CF Patients12 monthsImplementation of a quality improvement protocol to achieve a 5% increase in the FEV₁% predicted value in cystic fibrosis patients with impaired pulmonary function. Pulmonary function will be assessed using spirometry at baseline, six months, and 12 months.

Secondary

MeasureTime frameDescription
Serum HE4 Levels Before and After Pulmonary Function Improvement12 monthsMeasurement of HE4 levels in the serum of studied subjects before and after pulmonary function improvement. HE4 levels will be assessed using a standardized laboratory assay at baseline and after 12 months.

Countries

Egypt

Contacts

Primary ContactEman Fawzy, MD
eman199358@gmail.comEgypt: 201011778583
Backup ContactTerez Boshra
Terezboshra@gmail.com+201224035744

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026